MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.

Trial Details

NCT ID
NCT06414148
Phase
PHASE2
Sponsor
Peter MacCallum Cancer Centre, Australia
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Epcoritamab
  • Epcoritamab, lenalidomide and rituximab
Locations (sample)
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Herston, Queensland, Australia|-27.44453,153.01852
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Melbourne, Victoria, Australia|-37.814,144.96332

Key Eligibility Criteria

  • Age ≥ 16 years old at the time of signing the patient information and consent form (PICF)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • A diagnosis of relapsed/refractory large B-cell lymphoma
  • Received Therapeutic Good Administration (TGA) approved anti-CD19 CAR T-cell therapy as the most recent large B-cell lymphoma treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →